PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race

PatentVest (Nasdaq: MDBH) released a PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron,” analyzing 1,200+ patent documents across 50 programs to assess patent depth and long-term exclusivity.

Rhea-AI Summary

PatentVest (Nasdaq: MDBH) released a PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron,” analyzing 1,200+ patent documents across 50 programs to assess patent depth and long-term exclusivity.

Key findings: clinical efficacy converging at 12–16% weight loss, $71 billion injectable GLP-1 market, $47 billion in GLP-1 deal value since 2023, and looming patent cliffs for semaglutide (2031) and tirzepatide (2036).

Positive

• 1,200+ patent documents analyzed
• 50 oral small-molecule GLP-1 programs mapped
• $47 billion in GLP-1 deal value committed since 2023
• Clinical efficacy converging at 12–16% weight loss

Negative

• Most oral programs remain unpartnered
• Semaglutide patent cliff in 2031, tirzepatide cliff in 2036
• Dramatic disparities in patent depth among similar-stage programs

Argus Feb 26 session

-1.29% close to close 2.1x rel. volume Open Argus

Details

News Market Reaction – MDBH

On Feb 26, the day this news came out, MDBH closed 1.29% below the previous close. That session’s volume was 2.1x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Feb 26 session.

Key Figures

Injectable GLP-1 market size: $71 billion Patient penetration: <5% of eligible patients Oral GLP-1 programs: 50 programs +5 more

Injectable GLP-1 market size

$71 billion

Market built by injectable GLP-1 drugs

Patient penetration

<5% of eligible patients

Share of eligible patients reached by injectable GLP-1s

Oral GLP-1 programs

50 programs

Oral small-molecule GLP-1 programs racing for market share

Weight-loss efficacy range

12–16% weight loss

Clinical efficacy across leading oral small-molecule GLP-1 programs

Patent documents analyzed

1,200+ documents

Patents reviewed in the GLP-1 report

Clinical-stage programs

26 programs

Clinical-stage oral small-molecule GLP-1 programs in IP review

GLP-1 deal value

>$47 billion

GLP-1-related deal value committed since 2023

Mapped oral programs

50 total, 30 clinical

Oral small-molecule GLP-1 programs mapped worldwide

Historical Context

5 past events · Latest: Feb 02

5 events

1. Feb 02

   Board transitions update

   24h Move

   -3.1%

   Board changes and strategy alignment for public venture platform.

2. Jan 14

   PatentVest IP report

   24h Move

   +6.7%

   Space economy IP analysis highlighting competitive positions and risks.

3. Nov 20

   Q3 2025 update

   24h Move

   -3.4%

   Quarterly operational update and pipeline financing activities.

4. Nov 11

   Earnings call notice

   24h Move

   +4.5%

   Announcement of upcoming Q3 2025 business update webinar.

5. Oct 28

   Cardiac IP report

   24h Move

   -6.8%

   PatentVest report on $133B cardiac diagnostics IP landscape.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

glp-1, composition-of-matter, markush, formulation, +1 more

5 terms

glp-1 medical

"As injectable GLP-1 drugs built a $71 billion market while reaching less than 5%..."

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

composition-of-matter technical

"mapping composition-of-matter claims, Markush scope, formulation layers..."

A composition-of-matter is a legal description of a specific chemical or biological substance or mixture—think of it as the exact recipe and ingredients that make up a drug, material, or chemical product. For investors, ownership of a composition-of-matter patent can act like a locked recipe that keeps competitors out, protecting future sales and profit margins and reducing the risk that a product will be easily copied.

markush technical

"mapping composition-of-matter claims, Markush scope, formulation layers..."

Markush is a style of patent claim that groups multiple chemical structures or ingredients under a single description, effectively saying a product can contain A or B or C (or combinations) without listing each variant separately. Think of it like a recipe that allows several substitute ingredients — it can make intellectual property broader and harder for rivals to design around, so investors watch Markush claims because they affect how long a product can be protected, its licensing value, and competitive risk.

formulation technical

"Markush scope, formulation layers, and method-of-use protection."

A formulation is the specific recipe and physical form that combines an active ingredient with other components to create a usable medicine, supplement, or product — for example a pill, injection, cream, or inhaler. Investors care because formulation determines how well a product works, how safe and easy it is to make and sell, and how long it can be protected or differentiated in the market; think of it as the finished vehicle that delivers the engine (the active ingredient) to its destination.

method-of-use technical

"formulation layers, and method-of-use protection."

A method-of-use is a legal description of how a medicine, medical device, or technology is intended to be used to treat a specific condition or achieve a particular result. Think of it as the recipe for applying a product rather than the product itself; it can be protected by patents or regulatory approvals. Investors watch method-of-use protections because they can extend exclusive rights, affect future sales, create licensing opportunities, or trigger litigation that changes a product's commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Analysis of 1,200+ patent documents reveal which programs are building durable exclusivity, and which may not be

Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron.”

As injectable GLP-1 drugs built a $71 billion market while reaching less than 5% of eligible patients, fifty oral small-molecule programs are now racing to unlock the remaining 95%. Clinical efficacy across leading programs is converging in the 12–16% weight-loss range.

In this increasingly competitive field, long-term differentiation depends not only on clinical performance but also on the strength and defensibility of each program’s patent portfolio.

The report reviews more than 1,200 patent documents across 26 clinical-stage programs, mapping composition-of-matter claims, Markush scope, formulation layers, and method-of-use protection. The findings reveal dramatic disparities in patent depth between programs at similar development stages.

More than $47 billion in GLP-1-related deal value has been committed since 2023, yet most oral programs remain unpartnered. With semaglutide’s patent cliff approaching in 2031 and tirzepatide’s in 2036, long-term exclusivity will determine which assets become franchises and which face early generic pressure.

“When multiple drugs deliver similar weight-loss results, the competitive moat shifts beneath the surface,” said Javier Chamorro, Chief Operating Officer of PatentVest. “The difference between a broad genus claim and a narrow composition patent can determine who owns this market for the next twenty years.”

This analysis maps 50 oral small-molecule GLP-1 programs worldwide, including 30 in clinical development, and evaluates the IP positioning of leading assets from Eli Lilly, Novo Nordisk, Pfizer, Roche, AstraZeneca, Gilead, Structure Therapeutics, and others.

This is the first in a series of deep-dive analyses evaluating the structural and patent defensibility of each major program.

PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm designed to help visionary companies become technology leaders. Powered by a proprietary global IP database and a rigorous diligence methodology, PatentVest delivers actionable intelligence that reveals the structural advantages hidden beneath technology markets.

Read the full report here: https://insights.patentvest.com/https/www.patentvest.com/patentvest-pulse/the-oral-small-molecule-glp-1-race-beyond-orforglipron.

For more information or inquiries, please contact info@patentvest.com.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the PatentVest report say about the oral GLP-1 market opportunity for MDBH (MDBH)?

The report highlights a large unmet market: injectable GLP-1s built a $71 billion market while reaching under 5% of eligible patients. According to PatentVest, fifty oral programs are now racing to address the remaining patient opportunity and capture long-term share.

How many oral small-molecule GLP-1 programs and patents did PatentVest review in the Feb. 26, 2026 report?

PatentVest reviewed over 1,200 patent documents and mapped 50 oral programs worldwide. According to PatentVest, the analysis covered 26 clinical-stage programs and evaluated composition, formulation, and method-of-use protection.

What patent timelines in the PatentVest report could affect MDBH-listed assets (MDBH)?

The report flags key patent cliffs: semaglutide around 2031 and tirzepatide around 2036, which shape long-term exclusivity. According to PatentVest, these timelines increase the value of strong patent portfolios for franchise formation.

How does PatentVest assess clinical differentiation among oral GLP-1 candidates in the Feb. 26, 2026 report?

Clinical efficacy among leading oral programs is converging at 12–16% weight loss, reducing clinical separation. According to PatentVest, patent depth and claim breadth will therefore determine durable market differentiation.

What investor implications does the PatentVest Pulse report highlight for MDB Capital holdings (MDBH)?

The report implies IP strength will drive winner-take-most outcomes and partnership value in GLP-1 programs. According to PatentVest, investors should weigh patent breadth, partnership status, and patent cliffs when assessing program upside and risk.